Looking Closely at the Growth Curve for Cara Therapeutics Inc. (CARA) – News Heater
Home  »  Trending   »  Looking Closely at the Growth Curve for Cara Thera...

Looking Closely at the Growth Curve for Cara Therapeutics Inc. (CARA)

Cara Therapeutics Inc. (NASDAQ:CARA) went up by 23.76% from its latest closing price compared to the recent 1-year high of $18.93. The company’s stock price has collected 6.10% of gains in the last five trading sessions.

Is It Worth Investing in Cara Therapeutics Inc. (NASDAQ :CARA) Right Now?

Plus, the 36-month beta value for CARA is at 1.22. Opinions of the stock are interesting as 7 analysts out of 8 who provided ratings for Cara Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


The average price from analysts is $24.25, which is $16.64 above the current price. CARA currently public float of 45.03M and currently shorts hold a 9.35% ratio of that float. Today, the average trading volume of CARA was 604.21K shares.

CARA’s Market Performance

CARA stocks went up by 6.10% for the week, with a monthly drop of -33.04% and a quarterly performance of -12.61%, while its annual performance rate touched -29.19%. The volatility ratio for the week stands at 9.55% while the volatility levels for the past 30 days are set at 6.73% for Cara Therapeutics Inc.. The simple moving average for the period of the last 20 days is -15.78% for CARA stocks with a simple moving average of -28.38% for the last 200 days.

Analysts’ Opinion of CARA

Many brokerage firms have already submitted their reports for CARA stocks, with JP Morgan repeating the rating for CARA by listing it as a “Overweight.” The predicted price for CARA in the upcoming period, according to JP Morgan is $20 based on the research report published on March 08th of the current year 2022.

Canaccord Genuity, on the other hand, stated in their research note that they expect to see CARA reach a price target of $33. The rating they have provided for CARA stocks is “Buy” according to the report published on November 01st, 2021.

JP Morgan gave a rating of “Neutral” to CARA, setting the target price at $16 in the report published on August 03rd of the previous year.

CARA Trading at -20.39% from the 50-Day Moving Average

After a stumble in the market that brought CARA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.29% of loss for the given period.

Volatility was left at 6.73%, however, over the last 30 days, the volatility rate increased by 9.55%, as shares sank -30.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -11.09% lower at present.

During the last 5 trading sessions, CARA rose by +6.10%, which changed the moving average for the period of 200-days by -23.61% in comparison to the 20-day moving average, which settled at $10.74. In addition, Cara Therapeutics Inc. saw -24.30% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CARA starting from Posner Christopher, who sale 2,006 shares at the price of $12.67 back on Apr 04. After this action, Posner Christopher now owns 201,031 shares of Cara Therapeutics Inc., valued at $25,416 using the latest closing price.

Terrillion Scott, the Sec’y; Chief Compliance & G.C. of Cara Therapeutics Inc., sale 1,642 shares at $11.91 during a trade that took place back on Apr 01, which means that Terrillion Scott is holding 102,344 shares at $19,556 based on the most recent closing price.

Stock Fundamentals for CARA

Current profitability levels for the company are sitting at:

  • -386.85 for the present operating margin
  • +93.25 for the gross margin

The net margin for Cara Therapeutics Inc. stands at -384.06. Equity return is now at value -40.70, with -37.50 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 9.84.

Leave a Comment

Your email address will not be published.




Download Free eBook For


100% free. stop anytime no spam